The self-assembling processes underlining the capabilities of facially differentiated ("Janus") polycationic amphiphilic cyclodextrins (paCDs) as non-viral gene nanocarriers have been investigated by a pluridisciplinary approach. Three representative Janus paCDs bearing a common tetradecahexanoyl multitail domain at the secondary face and differing in the topology of the cluster of amino groups at the primary side were selected for this study. All of them compact pEGFP-C3 plasmid DNA and promote transfection in HeLa and MCF-7 cells, both in absence and in presence of human serum. The electrochemical and structural characteristics of the paCD-pDNA complexes (CDplexes) have been studied by using zeta potential, DLS, SAXS, and cryo-TEM. paCDs and pDNA, when assembled in CDplexes, render effective charges that are lower than the nominal ones. The CDplexes show a selfassembling pattern corresponding to multilamellar lyotropic liquid crystal phases, characterized by a lamellar stacking of bilayers of the CD-based vectors with anionic pDNA sandwiched among them. When exposed to human serum, either in the absence or in the presence of pDNA, the surface of the cationic CD-based vector becomes coated by a protein corona (PC) whose composition has been analysed by nanoLC-MS/MS. Some of the CDplexes herein studied showed moderate-to-high transfection levels in HeLa and MCF-7 cancer cells combined with moderate-to-high cell viabilities, as determined by FACS and MTT reduction assays. The ensemble of data provides a detail picture of the paCD-pDNA-PC association processes and a rational base to exploit the protein corona for targeted gene delivery on future in vivo applications.
Introduction
Nucleic acids (DNA or RNA) have become in the last decade an attractive source of therapeutic agents [1] . The interplay of a direct structure-activity relationship and a highly specific mode of action theoretically permit exploiting the cellular machinery in a predictable fashion to either stimulate or silence the expression of virtually any protein, with reduced toxicity and fewer side effects as compared with classical drugs. This is the basis of gene therapy (GT), an exciting branch of medicine that tries to cure diseases (genetic, neurologic, cardiovascular, infectious, or carcinogenic, etc.) at a molecular level, by repairing damaged cellular DNA, either by introducing (by means of a plasmid DNA) and expressing a copy of the affected or missing gene into the cells [2] [3] [4] [5] [6] [7] [8] or by inserting a small interfering RNA (siRNA) to silence and stop the expression of an abnormal gene, responsible of the cell disorder [9] [10] [11] [12] . Both approaches, either that one based on plasmid DNAs or on siRNAs, constitute nowadays the main strategies of GT on seeking for effectively restore healthy cell functioning.
Conventional drugs consist of bioactive species and a carrier, the former being normally the key of the design strategies. However, in the case of biomolecular drugs, such as nucleic acids, the carrier becomes a decisive protagonist. In the free state, nucleic acids are easily degraded by nucleases in biological fluids [13, 14] , and their membrane-crossing abilities and cellular uptake are seriously limited by their negative charge, inherently large size, and rigidity [15] . Formulation with appropriate delivery systems is thus essential for nucleic acids to overcome the physiological barriers, reach the target in a fully functional form and carry out the designed therapeutic function.
Viral gene vectors [16, 17] were first developed towards this end due to their high effectiveness. Yet, the use of viral vectors bear inherent risks, including immunogenicity and oncogenicity, which has boosted research on the design, synthesis, and characterization of non-viral carriers that may combine high transfection efficiencies with low cytotoxicity levels [18, 19] . In addition, for in vivo applications, these vectors must remain stable in the presence of blood or serum and, ideally, should be amenable to surface decoration with selective groups in order to recognize the target cells. The majority of non-viral vector formulations on record are based on cationic lipids [19, 20] , polymers [21] , nanoparticles [22] , and polysaccharides [12, 23] . More recently, gene delivery systems based on 3D molecular frameworks with precisely defined chemical structures, sizes, shape symmetry and functional group distributions have been developed [24] [25] [26] . Their intrinsic monodisperse character allows conducting systematic studies on the influence of vector modifications on the supramolecular interactions with nucleic acids and the consequences in transfection efficiencies [1] .
Within the context of molecular gene vectors, facially differentiated ("Janus") macrocyclic entities [24, 26, 27] , among which cyclodextrin (CD)-based derivatives are paradigmatic examples, have conquered a prominent position [28, 29] . CDs are biocompatible cyclic oligosaccharides consisting of α-1,4-linked glucopyranose units that define a cone-shape topology with well-differentiated faces. The Janus feature can be imparted by bidirectional functionalization with polycationic groups on one rim and hydrophobic chains on the opposite rim. Multihead-multitail polycationic amphiphilic CDs (paCDs) with self-assembling properties and biomimetic cell-membrane-crossing aptitudes, resembling both cationic lipids and cationic polymers, are thus accessed [30, 31] . In the presence of nucleic acids, they spontaneously form well-defined supramolecular nanocomplexes (hereinafter referred to as CDplexes) where the gene material is protected from degradation by enzymatic agents. Analogously to the wellknown lipoplexes and polyplexes [32] , CDplexes can elicit cellular uptake in physiological media and promote transfection [30, 31, 33, 34] . 5 Whereas in vitro transfection of immortalized cultured cells can be generally conducted in serum-free medium, some ex-vivo and any in vivo GT protocol will imply exposing of the nucleic acid-entrapping nanosystems to other biomolecules present in biological fluids. Non-specific interactions with these biomolecules may then decisively affect their fate in a biological environment [35, 36] . Indeed, once administered in vivo, the nanovectors are exposed to the biological fluids from which they adsorb proteins and other components, losing the bare vector identity to form a biologically active corona, known as the protein corona (PC) [37, 38] . This PC plays an important role in both the cellular recognition [39] and cell-membrane crossing capabilities (internalization process) of the nanovector [40] . It has also a clear effect on its time of circulation in the blood, so that knowing the proteomic profile of the corona surrounding a gene vector is crucial to optimize the transfection process. For instance, certain proteins like opsonins and, specially, immunoglobulins, fibrinogen and complement proteins are recognized by the macrophages favoring the phagocytosis and the rapid clearance of the vector from the bloodstream. On the other hand, the adsorption of apolipoproteins and serum albumin (dyopsonins) promote prolonged blood circulation half-life [41] . Successful delivery of therapeutic genes into cells will therefore require not only a high control of the physical-chemical parameters of the vector and vector-DNA nanocomplex, such as effective charges, chemical composition, size and structure, but also a deep knowledge on their interaction with serum proteins, the composition of the resulting PC and its impact in transfection capabilities and toxicity. Notwithstanding, up to date, most studies in this field are centered on the PC that forms around inorganic and organic nanoparticles [40, [42] [43] [44] , with only a few investigations evaluating the PC adsorbed on vector-DNA complexes [45, 46] . 6 This work is specifically focused on the biophysical and biochemical characterization of Janus paCD-pDNA CDplexes and their protein corona fingerprints as a function of the molecular paCD vector topology. We have chosen three different paCD representatives with a -cyclodextrin (CD) core, namely compounds ADM70, ADM105 and PBO234 (Scheme 1). The three molecular vectors share a C 7 -symmetrical skirt-type Janus architecture with a multitail lipophilic domain formed by fourteen hexanoyl groups that esterify the secondary hydroxyls, differing in the architecture of the multivalent cationic cluster installed at the primary positions. Thus, ADM70 displays a dendritic presentation of fourteen primary amino groups, ADM105 a linear arrangement of seven secondary and seven primary amino groups and PBO234 a heptavalent cluster of primary amino groups. ADM70 and ADM105 additionally incorporate a belt of seven thiourea groups at the primary face branches. All these structural elements have been previously found to impart good DNA compaction abilities to molecular gene vectors as well as good transfection capabilities to the corresponding vector-DNA complexes in cellulo and in vivo [33, 34] . We have first conducted a deep electrochemical and structural characterization of the bare nanovector and pDNA-loaded Janus paCD assemblies by using high precision experimental techniques including zeta potential, agarose gel electrophoresis, dynamic light scattering (DLS), small angle X-ray scattering (SAXS) and cryo-transmission electron microscopy (cryo-TEM). Given that what cells "see" and process in in vivo situation is not the bare complexes but the CDplexes-PC bioentity formed, we have evaluated the PC developed at the surface of CDplexes formulated with the three paCDs herein used when they interact with human plasma (HP), by means of nano liquid chromatography tandem mass spectrometry (nanoLC-MS/MS). Finally, transfection performances of the CDplexes and levels of cellular toxicity were further investigated in vitro by 7 fluorescence-activated cell sorting (FACS) and reduction of 3-(4,5-dymethylthiazol-2-y1)-2,5-diphenyl tetrazolium bromide (MTT assay), respectively. The final goal of this pluridisciplinary approach is obtaining a global picture of the optimal requirements for the preparation of the CDplexes, in an attempt of opening alternative trails that provide non-viral vectors with improved outputs of bioavailability and transfection efficiency (TE). Scheme 1. Structural characteristics of ADM70, ADM105 and PBO234.
Experimental section

Materials
The Janus paCDs used in this study, ADM70, ADM105 and PBO234 (Scheme 1), were prepared following the procedures previously reported [47] . Briefly, the synthesis of compound PBO234 was accomplished in four steps (i-iv) from commercially for the three polycationic amphiphilic cyclodextrins were consistent with those previously reported [47] . Most significantly, the 1 H and 13 C NMR spectra showed the typical single-spin system for fully C 7 -symmetrical molecules.
pEGFP-C3 Plasmid DNA (pDNA) was extracted from competent E. Coli bacteria previously transformed with pEGFP-C3, the extraction being carried out using GenElute HP Select plasmid Gigaprep Kit (Sigma Aldrich) following a protocol previously described [50, 51] . Sodium salt of calf thymus DNA (ctDNA), provided by Cryo-transmission electron microscopy (Cryo-TEM) experiments were run for paCD/pDNA CDplexes following the standard procedure [54, 55] . In these experiments, perforated Quantifoil R1.2/1.3 (hole diameter 1.2 µm) on a 400-mesh copper grid were used. Images were obtained using a Jeol JEM 2011 cryo-electron microscope operated at 200 kV, under low-dose conditions, and using different degrees of defocus (500-700 nm) to obtain an adequate phase contrast [56] . Images were recorded on a Gatan 794
Multiscan digital camera. Finally, the CCD images were processed and analyzed with a Digital Micrograph.
In order to carry on nanoLC-MS/MS analysis, 10 L peptide mixtures were separated by RP chromatography using the Dionex Ultimate 3000 (Dionex Corporation Sunnyvale, CA, USA). Samples were on-line preconcentrated on a -precolumn mass spectra correlating to at least two unique tryptic peptides were considered; minimum peptide identification probability was set at 95%, whereas protein identification probability was set at 99%. For protein quantitative analysis, Scaffold software allows the normalization of the spectral countings (normalized spectral countings, NSCs) and offers various statistical tests to identify significant abundance differences in two or more categories. The mean value of NSCs obtained in the three experimental replicates for each protein was further normalized to the protein molecular weight (MWNSC) and expressed as the relative protein quantity by applying Eq. (1):
where MWNSCk is the percentage molecular weight normalized NSC for protein k, and MW is the molecular weight in kDa for protein k. This correction takes into account the protein size and evaluates the actual contribution of each protein reflecting its relative protein abundance (RPA) in the "hard corona".
On transfection efficiency analysis, HeLa and MCF-7 cells were seeded in 12-well plate (150x10 3 cells/mL) and treated with paCD/GFP plasmid complexes alone or surrounded by protein corona for 48 h. Then, cells were detached with trypsin/EDTA, washed two times with cold PBS and acquired using a flow cytometer. Fluorescenceactivated cell sorting (FACS) analysis was performed using BD LSRFortessa equipped with 488 nm laser and with DIVA software (BD Biosciences, San Jose, CA, USA).
Cells were first gated using forward vs side scatter (FSC vs SSC) strategy to exclude debris (low events) and then analyzed for the specific 530 nm emission (FITC channel).
Data were analyzed using FlowJo software (FlowJo LLC data analysis software, Ashland, OR, USA). Transfection efficiencies (TE) were quantified by means of % GFP 
Results and discussion
Nanocomplex formation between non-viral gene vectors and nucleic acids is primarily driven by coulombic interactions. A proper characterization requires thus determination of the charges available in each partner, which are usually different from the nominal ones defined by the number of potentially ionizable groups. Regarding the oligonucleotide counterpart, studies reported in the literature [3, 12, 51, 53] 
<< -2).
For that reason, the characterization of the CDplexes must start with the determination of the effective charges of both the policationic Janus paCD and the pDNA, when forming the nanocomplex. At this respect, we have implemented a procedure to fulfil this objective based on a two-step protocol to determine: i) firstly, the effective charge of the cationic vector by characterizing the complex formed by this vector and double stranded linear DNA (linear DNA) for which the charge is well established (-2/bp); and ii) on a second step, the effective charge of the pDNA by characterizing the complex formed by the cationic vector, already of known charge (step i), and the pDNA in the same experimental conditions [51] [52] [53] . Briefly, the effective charge ratio ( ), defined as the quotient between the effective charges of the paCD amino groups and the DNA phosphate groups is given by the following equation:
where n + and n -are the number of moles of positive and negative charges of paCD and Thus, the net positive charges available for interaction with pDNA are around 33% of the nominal one, assuming full protonation of the amino groups, for the tetradecaamine derivatives ADM70 and ADM105, and only 25% for heptamine PBO234. This scenario is similar to that found for some CD polyrotaxane-based vectors [12] but sharply different from that encountered for cationic lipid gene vectors bearing quaternary amino groups, which normally yield their total nominal positive charges within a range of 10 % of uncertainty [19, 51, 57] . On the other hand, the plasmid used herein seems to be quite supercoiled at the experimental conditions used, since its available negative charge per bp is far away from the nominal value (-2/bp), yielding Cryo-TEM experiments further confirmed the multilamellar character of the CDplexes studied in this work. Fig. 4 shows a selection of micrographs among those taken for ADM105-pDNA CDplex that are representative of the ensemble of data (see Corona proteins are also classified by their physiological functions (Fig. 6 ). For reasonably good (70 -100%) at this  eff , both in absence and in presence of HP (Fig. 8) .
In an attempt to overcome such poor TE results, two strategies were designed: i) we increased the concentration of CDplexes/cell, but keeping  eff = 4, since recent results [58] point to this increase as a favorable factor to improve TE performances; and/or ii)
we increased  eff , with the risk of increasing cytoxicity levels as well. clearly reveals that the first strategy must be discarded for the CDplexes herein reported. On the other hand, as shown in Fig. 8 targeting ability, bio-distribution, cytotoxicity). In fact, in the literature, major works are discussing about mapping protein binding sites across the PC surface. In the absence of this piece of information, discussion about the potential role of corona proteins should be made, but kept at a minimum, as done in this work. Otherwise, the risk of speculation may be too high. 
Conclusions
This work was aimed to provide new insights in the fascinating processes governing pDNA complexation by monodisperse vectors of the Janus paCD family, in an attempt to delineate the mechanisms whereby differences in molecular structure translates into differences in transfection capabilities. For that purpose, three Janus CD-based compounds (ADM70, ADM105 and PBO234) have been thoroughly checked as potential nanocarriers of a pEGFP-C3 plasmid that codes for GFP expression to the interior of HeLa and MCF-7 cancer cells, both in the absence and presence of human serum. In a first level of organization, the vector molecular structure influences the effective positive charge available for interacting with the plasmid as well as the effective negative charge of the plasmid in the nanoaggregates. In fact, zeta potential study revealed that effective charges are lower than nominal ones both for the CDbased vectors (around 30% for ADMs and 25% for PBO234), and also for the pDNA, which renders a low percentage of its negative charge (less than 15%) when it is compacted by the nanocarriers. This is a potentially favourable finding since the weaker These transfection efficiencies were found to slightly decrease in the presence of biological media (HP), but in any case the values found were higher than those obtained with the control Lipofectamine. However, the effect of PC on the cell viability of CDplexes is not that easy to interpret. Probably, the specific PC composition and, in turn, its complex effect on nanocarrier processing by cell machinery, play a crucial role, although an accurate mapping of protein binding sites in the PC would be necessary to go further in these conclusions. In any case, the whole body of both biophysical and biochemical evidences obtained in this work allow us to conclude that the three paCDs proposed can be considered as potentially efficient nanocarriers in vitro and promising gen vectors for in vivo applications. Going further, among the three Janus paCDS nanovectors checked in this work, ADM70 seem to exhibit the most favourable features for in vitro gene therapy applications requiring serum-containing media, in total agreement with the already observed superiority of ADM70 formulations in in vivo transfection studies.
Highlights
-Effective charges (lower than nominal) potentially improve CDplexes transfection outputs.
-CDplexes show L  multilamellar patterns, quite appropriate to interact with cellular membranes.
-When exposed to human plasma CDplexes are covered by a rich protein corona.
-Optimized CDplexes exhibit high TE and very low cytotoxicity in HeLa and MCF7
cancer cells.
-TE/cell viability outputs of optimized CDplexes overcome those of the standard Lipofectamine. 
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